These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 8615167

  • 21. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia.
    Berding G, Gratz KF, Kolbe H, Meyer GJ, Dengler R, Knoop BO, Hundeshagen H.
    Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of Parkinson's disease.
    van den Munckhof P, Gilbert F, Chamberland M, Lévesque D, Drouin J.
    J Neurochem; 2006 Jan; 96(1):160-70. PubMed ID: 16269007
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
    Staedt J, Stoppe G, Kögler A, Riemann H, Hajak G, Munz DL, Emrich D, Rüther E.
    J Neural Transm Gen Sect; 1995 Jan; 99(1-3):187-93. PubMed ID: 8579804
    [Abstract] [Full Text] [Related]

  • 30. [Brain SPECT with 123I-lisuride in patients with Parkinson's disease and controls].
    Hierholzer J, Cordes M, Schelosky L, Richter W, Schrag A, Poewe W, Schulze PE, Semmler W, Eichstädt H, Felix R.
    Nuklearmedizin; 1995 Aug; 34(4):141-5. PubMed ID: 7675643
    [Abstract] [Full Text] [Related]

  • 31. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB, Bernardi G.
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [Abstract] [Full Text] [Related]

  • 32. Visualizing vesicular dopamine dynamics in Parkinson's disease.
    de la Fuente-Fernández R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ.
    Synapse; 2009 Aug; 63(8):713-6. PubMed ID: 19391152
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A, Molinari SP, Kollmeier B, Yahr MD.
    Adv Neurol; 1996 Aug; 69():3-11. PubMed ID: 8615142
    [No Abstract] [Full Text] [Related]

  • 39. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.
    Schwarz J, Tatsch K, Arnold G, Ott M, Trenkwalder C, Kirsch CM, Oertel WH.
    Neurology; 1993 Dec; 43(12 Suppl 6):S17-20. PubMed ID: 8264906
    [Abstract] [Full Text] [Related]

  • 40. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
    Hierholzer J, Cordes M, Schelosky L, Sander B, Böck JC, David I, Horowski R, Poewe W.
    Rofo; 1993 Jul; 159(1):86-90. PubMed ID: 8334264
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.